M&T Bank Corp Has $2.35 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

M&T Bank Corp increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 108,951 shares of the company’s stock after acquiring an additional 13,375 shares during the quarter. M&T Bank Corp’s holdings in Kenvue were worth $2,346,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Empirical Finance LLC bought a new stake in shares of Kenvue in the third quarter valued at about $336,000. UniSuper Management Pty Ltd bought a new stake in shares of Kenvue during the third quarter valued at approximately $35,544,000. Citizens Business Bank acquired a new position in shares of Kenvue in the third quarter valued at $2,507,000. Fifth Third Bancorp lifted its position in Kenvue by 35.3% in the fourth quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after purchasing an additional 72,435 shares during the period. Finally, Clearbridge Investments LLC boosted its stake in Kenvue by 364.6% during the third quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock worth $9,725,000 after buying an additional 380,071 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. HSBC increased their target price on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a report on Wednesday. Sanford C. Bernstein started coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. William Blair began coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. Finally, Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $24.38.

Kenvue Stock Performance

Kenvue stock opened at $20.45 on Thursday. The stock’s fifty day moving average price is $19.87 and its two-hundred day moving average price is $20.12. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. The business’s revenue for the quarter was down 24.9% on a year-over-year basis. Analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date is Tuesday, May 7th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.